Publication Name	World Journal of Gastroenterology
Manuscript ID	25766
Country	Spain

Received	2016-03-22 08:42
Peer-Review Started	2016-03-22 17:26
To Make the First Decision	2016-05-12 14:37
Return for Revision	2016-05-12 15:34
Revised	2016-05-25 01:30
Second Decision	2016-06-06 08:29
Accepted by Journal Editor-in-Chief
Accepted by Executive Editor-in-Chief	2016-06-15 18:44
Articles in Press	2016-06-15 18:44
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2016-07-18 13:53
Publish the Manuscript Online	2016-07-29 20:32

ISSN	1007-9327 (print) and 2219-2840 (online)
Open Access	This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright	© The Author(s) 2016. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Virology
Manuscript Type	Topic Highlights
Article Title	Treatment of chronic hepatitis C with direct-acting antivirals: The role of resistance
Manuscript Source	Invited Manuscript
All Author List	Miguel Jiménez-Pérez, Rocío González-Grande, Pilar España Contreras, Isabel Pinazo Martínez, Jesús de la Cruz Lombardo and Raúl Olmedo Martín
Funding Agency and Grant Number
Corresponding Author	Miguel Jiménez-Pérez, MD, UGC de Aparato Digestivo, Unidad de Hepatología-Trasplante Hepático, Hospital Universitario Regional de Málaga, Avenida Carlos Haya, 29010 Malaga, Spain. mjimenezp@commalaga.com
Key Words	Direct-acting antivirals; Resistance; Treatment; Hepatitis C virus
Core Tip	The use of direct-acting antivirals (DAAs) to treat chronic hepatitis C has resulted in a significant increase in rates of sustained viral response as com-pared with the standard treatment of peginterferon/ribavirin. The presence of resistance-associated variants (RAVs) can reduce viral sensitivity to DAAs, thus limiting the efficacy of these drugs . As well as the presence of RAVs, virological failure is generally associated with other factors related with a poor response. Nonetheless, therapeutic failure can still occur in the absence of detectable RAVs and after the use of highly effective DAAs, so that the true clinical impact of the RAVs remains to be determined.
Publish Date	2016-07-29 20:32
Citation	Jiménez-Pérez M, González-Grande R, España Contreras P, Pinazo Martínez I, de la Cruz Lombardo J, Olmedo Martín R. Treatment of chronic hepatitis C with direct-acting antivirals: The role of resistance. World J Gastroenterol 2016; 22(29): 6573-6581
URL	http://www.wjgnet.com/1007-9327/full/v22/i29/6573.htm
DOI	http://dx.doi.org/10.3748/wjg.v22.i29.6573

Full Article (PDF)	WJG-22-6573.pdf
Full Article (Word)	WJG-22-6573.doc
Manuscript File	25766-Review.docx
Answering Reviewers	25766-Answering reviewers.pdf
Audio Core Tip	25766-Audio core tip.wav
Conflict-of-Interest Disclosure Form	25766-Conflict-of-interest statement.pdf
Copyright License Agreement	25766-Copyright assignment.pdf
Non-Native Speakers of English Editing Certificate	25766-Language certificate.pdf
Peer-review Report	25766-Peer-review(s).pdf
Scientific Misconduct Check	25766-Scientific misconduct check.pdf
Scientific Editor Work List	25766-Scientific editor work list.pdf